NEI Psychopharm

Neuroscience Education Institute (NEI) is committed to help raise the standard of mental health care by providing imaginative medical education

[NEI Psychopharm @neiglobal]

Methamphetamine use disorder affects millions worldwide, yet no FDA-approved treatment exists. In a phase 3 trial, mirtazapine 30 mg/day significantly reduced methamphetamine use compared with placebo and was generally well tolerated, supporting its potential as an effective treatment option. Read more https://t.co/a0DKtg486y

[NEI Psychopharm @neiglobal]

Present Your Research at 2026 NEI Fall Congress! The Scientific Poster Session provides an opportunity to showcase your research, clinical findings, innovative programs, and quality improvement initiatives to a community of mental health professionals.

Share your work, engage in meaningful discussions with colleagues, and contribute to advancing psychiatric care. Poster abstract submissions are due August 3, 2026. Submit now https://t.co/cOyuun2c1a

[NEI Psychopharm @neiglobal]

Lithium remains one of the most effective treatments for bipolar disorder, with growing evidence supporting broader benefits including mood stabilization, neuroprotection, and potential prevention of cognitive decline, yet it remains underutilized in clinical practice. Read more https://t.co/ML7ted82NQ

[NEI Psychopharm @neiglobal]

Mental Health Awareness Month may be ending, but our commitment to improving patient care continues every day.

At NEI, we believe that helping more patients starts with helping the professionals who treat them. We are proud to provide mental health clinicians with trusted clinical tools, practice resources, and the latest evidence-based education to support better outcomes for the patients they serve.

Thank you to the mental health professionals whose dedication makes a difference every day!

#MentalHealthAwarenessMonth #Psychiatry #ContinuingEducation #Psychopharmacology

[NEI Psychopharm @neiglobal]

Today on World Schizophrenia Day, NEI joins the global effort to raise awareness, promote understanding, and help reduce stigma surrounding schizophrenia.
View resources 👉 https://t.co/ELxEsTHU31

[NEI Psychopharm @neiglobal]

Thank you to everyone who stopped by the NEI Booth at the 2026 APA Annual Meeting in San Francisco! It was a pleasure connecting with so many passionate mental health professionals and having meaningful conversations about the future of psychiatric care.
#APAAM26

[NEI Psychopharm @neiglobal]

Join us at the 2026 NEI Fall Congress at The Broadmoor in Colorado Springs.

This is where psychiatry comes together for practical education, meaningful conversations, and the latest insights in mental health care. From expert-led sessions to real-world clinical strategies, you’ll leave with tools you can use right away. Register today https://t.co/DRWcC4i3ya

#NEICongress #Psychiatry #MentalHealth #Psychopharmacology #CME

[NEI Psychopharm @neiglobal]

Heading to the APA Annual Meeting? Stop by the NEI Booth (#649) in the Exhibit Hall and say hello!
Learn more about NEI Membership, NEI Spring Congress, NEI Fall Congress, practical point-of-care tools, CME opportunities, and psychopharmacology education designed to support today’s clinicians.

We look forward to connecting with you at APA! #APAAM26

[NEI Psychopharm @neiglobal]

Get a first look at the sessions and topics shaping this year’s NEI Fall Congress. Talk titles are now live. Start exploring the ideas and conversations coming to the stage. 👀 https://t.co/IRxiillWJF

[NEI Psychopharm @neiglobal]

Children’s Mental Health Awareness Day highlights the importance of recognizing and addressing the mental health needs of children and adolescents because early support can change lives.

NEI is committed to empowering the clinicians who care for young patients with mental health disorders. We continue to expand our resources to provide practical tools, expert education, and evidence-based guidance for pediatric care.

Explore what’s available to support your practice:
• Child & Adolescent Psychiatry Academy | November 4, 2026
• NEI Prescribe app with a dedicated Child & Adolescent section
• Encore presentations featuring evidence-based therapeutic strategies
• Clinical Toolkit with treatment algorithms for ADHD, Anxiety, Bipolar Disorder, Insomnia, MDD, and OCD
• and much more, visit https://t.co/b70H2qxSXc

[NEI Psychopharm @neiglobal]

A new network meta-analysis evaluates 22 randomized controlled trials comparing five FDA-approved adjunctive antipsychotics for adults with MDD and inadequate antidepressant response. For the first time, a Bayesian approach establishes a clear hierarchy of efficacy and acceptability, offering actionable insights for treatment selection. Read more https://t.co/WQQmcaDKDG

[NEI Psychopharm @neiglobal]

This #NationalNursesWeek, NEI is honored to recognize the nurses whose dedication and expertise elevate patient care every day. Your dedication to your patients and the healthcare community motivates us to continue building education designed to support your work and professional growth.

[NEI Psychopharm @neiglobal]

Dr. Andy Cutler sits down with Dr. Neill Epperson to break down how to assess cognitive complaints in women. They explore how to distinguish between ADHD, hormonal shifts like perimenopause, mood and anxiety disorders, and normal age-related changes. https://t.co/qWRj3CcKiP

[NEI Psychopharm @neiglobal]

Clinical trials may show statistical significance, but translating results into real-world patient care can be challenging. At NEI Spring Congress, Dr. Leslie Citrome reviewed practical ways to interpret data beyond p-values, including Needed to Treat (NNT), and Number Needed to Harm (NNH), to better assess clinical relevance and guide treatment decisions.

[NEI Psychopharm @neiglobal]

The U.S. Food and Drug Administration has approved oral dextromethorphan-bupropion for the treatment of agitation associated with Alzheimer disease. Read more: https://t.co/nN6OWoUiMW

[NEI Psychopharm @neiglobal]

Psychotropic polypharmacy is common, but clear guidance on when to stop medications has been lacking. A new international consensus offers practical direction on when and how to deprescribe. Read more https://t.co/NGbSRKHe23

[NEI Psychopharm @neiglobal]

Bring NEI Spring Congress to you. Access world-class psychiatric education and practical insights from anywhere. Join virtually to watch expert sessions, engage in live Q&A, and earn CME/CE credit in real time. Register today at https://t.co/oXe6ZY7OzO

[NEI Psychopharm @neiglobal]

It’s Saturday morning. ☀️ Log in now to join Drs. Jeffrey Strawn and Karl Doghramji as they explore the intersection of sleep regulation and wellness in mental health care. Not registered yet? There’s still time. Registration is free but required: https://t.co/2YgKrJGYxp

[NEI Psychopharm @neiglobal]

Posttraumatic stress disorder (PTSD) remains a chronic, often disabling condition, and current first-line treatments like SSRIs can fall short with slow onset and limited efficacy. A novel agent, TSND-201 (methylone), is drawing attention as a potential rapid-acting option. Read more https://t.co/O8iC0DpOzy